论文标题：A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid
期刊：
作者：Chien Ho et al
发表时间：2017/11/23
数字识别码：10.1038/s41598-017-16293-6
原文链接：
《明升体育app手机版》发表的A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid一文中，美国卡内基梅隆大学的Chien Ho和他的同事们开发了一种新方法，使用FDA批准的营养补充剂脂肪乳剂，来暂时性地减弱网状内皮系统吸收纳米药物的能力，这是纳米药物递送中的一个主要挑战，并且会导致脱靶毒性。
作者们设计了一个实验，用含铂抗癌纳米药物和三种FDA批准的纳米药物——紫杉醇纳米制剂Abraxane，硫酸长春新碱脂质体Marqibo和安能得Onivyde——在添加或不添加脂肪乳剂情况下，在大鼠中测试了他们的方法，以确定它们在肝脏、脾脏和肾脏中的毒性。实验证明了该方法在纳米药物递送上具有提高生物利用度和降低毒性的潜力。他们的研究显示，脂肪乳剂处理对肿瘤生长没有有害作用，并且对含铂纳米药物的抗肿瘤功效以及HT-29异种移植小鼠模型中的动物存活率没有负面影响。这是一种通用方法，无需对纳米药物进行额外修饰，适用于任何已批准的和正在开发中的纳米药物，从而有助于其向临床转化。
摘要：We have developed a new strategy to temporarily blunt the reticuloendothelial system uptake of nanodrugs, a major challenge for nanodrug delivery and causing off-target toxicities, using an FDA approved nutrition supplement, Intralipid. We have tested our methodology in rats using an experimental platinum-containing anti-cancer nanodrug and three FDA approved nanodrugs, Abraxane, Marqibo, and Onivyde, to determine their toxicities in liver, spleen, and kidney, with and without the addition of Intralipid. Our method illustrates its potentials to deliver nanodrugs with an increase in the bioavailability and a decrease in toxicities. Our study shows that Intralipid treatment exhibits no harmful effect on tumor growing and no negative effect on the anti-tumor efficacy of the platinum-containing nanodrug, as well as animal survival rate in a HT-29 xenograft mouse model. Our methodology could also be a valuable complement/supplement to the “stealth” strategies. Our approach is a general one applicable to any approved and in-development nanodrugs without additional modification of the nanodrugs, thus facilitating its translation to clinical settings.
阅读论文全文请访问：
期刊介绍： is an online, open access journal from the publishers of Nature. We publish scientifically valid primary research from all areas of the natural and clinical sciences.
The 2016 journal metrics for Scientific Reports are as follows:
•2-year impact factor: 4.259
•5-year impact factor: 4.847
•Immediacy index: 0.647
（来源：明升手机版(明升官网)）
特别声明：本文转载仅仅是出于传播信息的需要，并不意味着代表本网站观点或证实其内容的真实性；如其他媒体、网站或个人从本网站转载使用，须保留本网站注明的“来源”，并自负版权等法律责任；作者如果不希望被转载或者联系转载稿费等事宜，请与我们接洽。
